Introduction {#sec1}
============

The morbidity of esophagogastric junction adenocarcinoma (EGJA) is promoting rapidly, both in developing and developed contries \[[@B1]\]. EGJA comprises a vital portion esophageal and gastric cancer, with an increasing ratio. It is reported that EGJA is a common fatal tumor in China. EGJA is regarded as an entity with a specific clinical feature and molecular profile. The potential protective factor or a real cause of EGJA is unclear. Thus, an understanding of the potential risk factors influencing the development EGJA biology may be helpful to diagnosis and prognostic assessment for the supervision of EGJA patients.

During the activation of T lymphocytes, they can express some receptors for receiving various signals. B- and T-lymphocyte attenuator (BTLA), also named CD272, is a most recently identified and studied member of the immune globulin (Ig) superfamily \[[@B4]\]. BTLA is a glycoprotein and it contains two tyrosine-based inhibitory motifs \[[@B8]\]. During activation, BTLA is not expressed on T helper type 2 (Th2) cells, but Th1 cells. The expression of BTLA on T cells participates in negative regulation of T cell and then leads to an decreased T-lymphocytes proliferation \[[@B9]\]. Recently, many investigations have focused on the relationship of BTLA with inflammation, autoimmune disease and cancer. Shi et al. reported that BTLA-herpes virus entry mediator (HVEM) checkpoint axis might be implicated in the regulation of inflammation in liver \[[@B10]\]. A previous study indicated that the up-regulation of BTLA gene expression and soluble BTLA (sBTLA) was validated in thymoma-associated myasthenia gravis \[[@B11]\]. A prognostic investigation showed that the levels of immune checkpoints sBTLA could be considered as a biomarker for unresectable pancreatic adenocarcinoma cases with a poor survival \[[@B12]\]. A functional study identified that IFN-γ level in circulating T-lymphocytes could be promoted by inhibiting BTLA/HVEM pathway \[[@B13]\]. Additionally, Feng et al. \[[@B14]\] and Lan et al. \[[@B15]\] reported that the level of BTLA expression in gastric carcinoma (GC) might be a useful biomarker for the evalution of GC prognosis.

Single-nucleotide polymorphisms (SNPs) in *BTLA* gene are likely to affect the role of BTLA protein. Some studies have kept a watchful eye on the correlation of *BTLA* variants with the development of cancer \[[@B16]\]. Fu et al*.* reported that the frequencies of *BTLA* rs1844089 and rs2705535 SNPs may alter the risk of breast cancer \[[@B17]\]. In Polish population, it was found that *BTLA* rs1982809 G\>A, a 3′-UTR SNP, might be a low-penetrating risk factor for the development of renal cell carcinoma \[[@B18]\]. In addition, another study indicated that *BTLA* rs1982809 G and rs2705511 C alleles were more frequent in patients with chronic lymphocytic leukemia compared with healthy controls \[[@B16]\]. In view of the vital role in cancer development and progress, we supposed that *BTLA* SNPs might be correlated with EGJA susceptibility. Here, *BTLA* tagging SNPs (rs16859629 T\>C, rs1982809 G\>A, rs2171513 G\>A and rs3112270 A\>G) were selected. The aim of the present study was to identify the association of *BTLA* tagging SNPs with risk of EGJA.

Materials and methods {#sec2}
=====================

Subjects {#sec2-1}
--------

The present study involved 1236 new incident EGJA patients and 1540 cancer-free controls. Among these patients, 393 cases patients diagnosed with EGJA and treated at two affiliated hospitals of Fujian Medical University \[Union Hospital (Fuzhou, China) and Fujian Cancer Hospital (Fuzhou, China)\] from January 2014 to June 2018. In addition, 843 patients with EGJA were from Jiangsu University People's Hospital (Zhenjiang, China) from January 2008 to June 2018. Siewert type was used in our study \[[@B19]\]. Here, all EGJA cases included were Siewert type II (their centre within 1 cm proximal and 2-cm distal of the anatomical cardia). All included EGJA cases were diagnosed at the first time with histopathological test. For EGJA cases, the major included criteria were: (a) individuals who did not have a history of other cancers, (b) without any immunological diseases and (c) EGJA patients were not treated wtih any chemotherapy and/or radiotherapy before the enrolment. We recruited 1540 cancer-free subjects as controls matching to the EGJA patients by sex, year of birth (±5 year) and ethnicity (Eastern Chinese Han nationality). They were from the hospitals mentioned above for regular health examination. The major included criteria for controls were: (a) cancer-free individuals, (b) without any immunological diseases, (c) sex and age matching to EGJA cases and (d) Han nationality who living in Eastern China. Each patitcipant signed a consent form. The experimental protocol was authorized by the ethics committees of the Jiangsu University.

Selection of SNPs {#sec2-2}
-----------------

The tagging SNPs of *BTLA* \[from 112458030 to 112504757 in chromosome 3 (extending 5 Kb, upstream and downstream, respectively)\] were structured and collected from Chinese populations via Genome Variation Server data. The criteria of tagging SNPs selection were described in our previous studies \[[@B20],[@B21]\].

DNA extraction {#sec2-3}
--------------

Genomic DNA was extracted from the colletced blood samples with the Promega DNA Kit (Promega, Madison, U.S.A.), according to the explanatory memorandum. A 2-μl DNA was droped in NanoDrop ND-1000 spectrophotometer (Wilmington, U.S.A.) to evaluate concentration and purity of DNA sample.

Genotyping {#sec2-4}
----------

The genotypes of *BTLA* rs16859629, rs1982809, rs2171513 and rs3112270 SNPs were analyzed using a SNPscan Kit (Genesky Biotechnologies Inc., Shanghai, China) as described previously \[[@B22]\]. PCR process was conducted in a 20-μl mixture volume in 96-well plates. ABI 3730xl DNA Analyzer was used to identify the genotype. The data of the sequencing were read by GeneMapper 4.1 (AppliedBiosystems, U.S.A.). One hundred and eleven DNA specimens were randomly chosen for repeat genotyping by another person in a blind fashion, and the obtained variants were concordant.

Statistical method {#sec2-5}
------------------

For each locus in *BTLA* gene, an online *χ*^2^ test was used to assess the Hardy--Weinberg equilibrium (HWE) \[[@B25]\]. The Student *t* test was performed to deal with continuous variables of demographic characteristics between two groups. And *χ*^2^ test was harnessed to handle the categorical variables (e.g., age, sex, cigarette using and alcohol consumption) and variant distributions of *BTLA* SNPs between two groups. The haplotypes of *BTLA* gene were evaluated by SHESIS software \[[@B26]\]. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of the correlation of *BTLA* SNPs with the risk of EGJA. Multiple logistic regression analysis was harnessed to check the distribution of *BTLA* rs16859629, rs1982809, rs2171513 and rs3112270 genotypes between two groups. Subgroup analyses between the *BTLA* variants and characteristic variables were also conducted. The adjusted *P* values, ORs and 95% CIs were calculated by adjustment for age, sex, cigarette using and drinking. A *P* \< 0.05 (two-way tests) was defined as significance in all statistical tests. All statistical analyses described previously were performed in SAS 9.4 software (SAS Institute Inc., Cary, NC, U.S.A.). Using PS software (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>), the power value (*α* = 0.05) was calculated \[[@B27],[@B28]\]. We also used the false-positive report probability (FPRP) to determine the significant findings \[[@B29]\].

Results {#sec3}
=======

Baseline characteristics {#sec3-1}
------------------------

[Table 1](#T1){ref-type="table"} summarizes age, sex, cigarette using and alcohol consumption in two groups. EGJA patients had a mean age of 64.28 ± 8.64 years. The age and sex ratio was not significant between two groups (*P* = 0.408 and *P* = 0.485, respectively). The success rate of *BTLA* rs16859629, rs1982809, rs2171513 and rs3112270 genotyping was of high quality (\>97%) ([Table 2](#T2){ref-type="table"}). We pressented the data of minor allele frequency (MAF) in [Table 2](#T2){ref-type="table"}. In control group, the frequencies of genotype distribution met HWE ([Table 2](#T2){ref-type="table"}).

###### Distribution of selected demographic variables and risk factors in this case--control study

  Variable         Overall cases (*n* = 1236)   Overall controls (*n* = 1540)   *P*[^1^](#T1TFN1){ref-type="table-fn"}           
  ---------------- ---------------------------- ------------------------------- ---------------------------------------- ------- -------------
  Age (years)      64.28 (±8.64)                64.17 (±10.32)                  0.775                                            
  Age (years)                                                                                                                    0.408
    \< 64          568                          45.95                           732                                      47.53   
    ≥64            668                          54.05                           808                                      52.47   
  Sex                                                                                                                            0.485
    Male           885                          71.60                           1084                                     70.39   
    Female         351                          28.40                           456                                      29.61   
  Smoking status                                                                                                                 0.087
    Never          884                          71.52                           1146                                     72.73   
    Ever           352                          28.48                           394                                      27.27   
  Alcohol use                                                                                                                    **\<0.001**
    Never          1,028                        83.17                           1359                                     88.25   
    Ever           208                          16.83                           181                                      11.75   

Two-sided *χ*^2^ test and Student's *t* test.

###### Primary information for *BTLA* targging SNPs (rs2171513 G\>A, rs3112270 A\>G, rs1982809 G\>A and rs16859629 T\>C)

  Genotyped polymorphisms                                                              rs2171513 G\>A   rs3112270 A\>G   rs1982809 G\>A   rs16859629 T\>C
  ------------------------------------------------------------------------------------ ---------------- ---------------- ---------------- -----------------
  Chr                                                                                  3                3                3                3
  Position_38                                                                          112466080        112461797        112463893        112471533
  Region                                                                               3′-UTR           Promoter         3′-UTR           intron_variant
  MAF[^1^](#T2TFN1){ref-type="table-fn"} in database (1000 g Chinese Han populatons)   0.188            0.269            0.216            0.067
  MAF in our controls (*n* = 1540)                                                     0.196            0.280            0.256            0.084
  *P* value for HWE[^2^](#T2TFN2){ref-type="table-fn"} test in our controls            0.625            0.114            0.796            0.898
  \% Genotyping value                                                                  98.34%           98.56%           98.52%           97.48%

MAF, minor allele frequency.

HWE, Hardy--Weinberg equilibrium.

Relationship of *BTLA* rs16859629, rs1982809, rs2171513 and rs3112270 SNPs with EGJA {#sec3-2}
------------------------------------------------------------------------------------

The genotype distributions and frequencies of *BTLA* rs16859629, rs1982809, rs2171513 and rs3112270 genotypes are presented in [Table 3](#T3){ref-type="table"}. In a single SNP analysis, the *BTLA* rs2171513 G\>A genotype frequencies were 62.83% (GG), 32.67% (GA) and 4.50% (AA) in EGJA patients and 63.70% (GG), 32.27% (GA) and 4.03% (AA) in the cancer-free controls. When the *BTLA* rs2171513 GG genotype was defined as the reference, the *BTLA* rs2171513 GA genotype was not correlated with the susceptibility for EGJA (GA versus GG: adjusted OR = 1.04, 95% CI: 0.88--1.22, *P* = 0.668); the *BTLA* rs2171513 AA genotype was not correlated with the susceptibility for EGJA (AA versus GG: adjusted OR = 1.23, 95% CI: 0.83--1.81, *P* = 0.302). In addition, the *BTLA* rs2171513 GA/AA genotypes did not conferred the risk to EGJA in the dominant model (GA/AA versus GG: adjusted OR = 1.06, 95% CI: 0.90--1.24, *P* = 0.497). In the recessive genetic compared model, when the *BTLA* rs2171513 GG/GA genotypes were defined as a reference, the *BTLA* rs2171513 AA genotype was not correlated with susceptibility for EGJA (AA versus GG/GA: adjusted OR = 1.21, 95% CI: 0.83--1.78, *P* = 0.327) ([Table 3](#T3){ref-type="table"}). No association was also found between *BTLA* rs3112270 A\>G, rs1982809 G\>A and rs16859629 T\>C SNPs and the susceptibility of EGJA ([Table 3](#T3){ref-type="table"}).

###### Logistic regression analyses of associations between *BTLA* targging SNPs (rs2171513 G\>A, rs3112270 A\>G, rs1982809 G\>A and rs16859629 T\>C) and the risk of EGJA

  Genotype          EGJA case (*n* = 1236)   Controls (*n* = 1540)   Crude OR (95%CI)   *P*     Adjusted OR[^1^](#T3TFN1){ref-type="table-fn"} (95% CI)   *P*                         
  ----------------- ------------------------ ----------------------- ------------------ ------- --------------------------------------------------------- ------- ------------------- -------
  rs2171513 G\>A                                                                                                                                                                      
  GG                754                      62.83                   985                64.38   1.00                                                              1.00                
  GA                392                      32.67                   489                31.96   1.05(0.89--1.23)                                          0.580   1.04(0.88--1.22)    0.668
  AA                54                       4.50                    56                 3.66    1.26(0.86--1.85)                                          0.241   1.23(0.83--1.81)    0.302
  GA+AA             446                      37.17                   545                35.62   1.07(0.91--1.25)                                          0.404   1.06(0.90--1.24)    0.497
  GG+GA             1146                     95.50                   1,474              96.34   1.00                                                              1.00                
  AA                54                       4.50                    56                 3.66    1.24(0.85--1.82)                                          0.269   1.21(0.83--1.78)    0.327
  A allele          500                      20.83                   601                19.64                                                                                         
  rs3112270 A\>G                                                                                                                                                                      
  AA                639                      52.99                   782                51.11   1.00                                                              1.00                
  AG                472                      39.14                   641                41.90   0.90(0.77--1.06)                                          0.197   0.90(0.77--1.06)    0.192
  GG                95                       7.88                    107                6.99    1.09(0.81--1.46)                                          0.582   1.10 (0.82--1.48)   0.538
  AG+GG             567                      47.02                   748                48.89   0.93(0.80--1.08)                                          0.330   0.93(0.80--1.08)    0.333
  AA+AG             1111                     92.13                   1423               93.01   1.00                                                              1.00                
  GG                95                       7.88                    107                6.99    1.14(0.85--1.52)                                          0.380   1.15(0.86--1.53)    0.343
  G allele          662                      27.45                   855                27.94                                                                                         
  rs1982809 G\>A                                                                                                                                                                      
  GG                668                      55.44                   846                55.29   1.00                                                              1.00                
  GA                461                      38.26                   586                38.30   1.00 (0.85--1.17)                                         0.964   1.00(0.85--1.17)    0.984
  AA                76                       6.30                    98                 6.41    0.98(0.72--1.35)                                          0.911   1.00(0.85--1.37)    0.980
  GA+AA             537                      44.56                   684                44.71   0.99(0.85--1.16)                                          0.941   1.00(0.86--1.16)    0.979
  GG+GA             1129                     93.70                   1432               93.59   1.00                                                              1.00                
  AA                76                       6.30                    98                 6.41    0.98(0.72--1.34)                                          0.917   1.00(0.73--1.36)    0.983
  A allele          613                      25.44                   782                25.56                                                                                         
  rs16859629 T\>C                                                                                                                                                                     
  TT                1028                     85.74                   1265               83.94   1.00                                                              1.00                
  TC                158                      13.18                   231                15.33   0.84(0.68--1.05)                                          0.122   0.84(0.67--1.04)    0.106
  CC                13                       1.08                    11                 0.73    1.45(0.65--3.26)                                          0.363   1.39(0.62--3.13)    0.426
  CT+CC             171                      14.26                   242                16.06   0.87(0.70--1.08)                                          0.197   0.86(0.70--1.07)    0.166
  TT+CT             1186                     98.92                   1496               99.27   1.00                                                              1.00                
  CC                13                       1.08                    11                 0.73    1.49(0.67--3.34)                                          0.332   1.43(0.64--3.21)    0.389
  C allele          184                      7.67                    253                8.39                                                                                          

Adjusted for age, sex, smoking, status of Chronic hepatitis B virus infection and drinking.

Bold values are statistically significant (*P* \< 0.05).

Relationship of *BTLA* rs16859629, rs1982809, rs2171513 and rs3112270 SNPs with EGJA in subgroup analysis {#sec3-3}
---------------------------------------------------------------------------------------------------------

[Table 4](#T4){ref-type="table"} presents the variant frequencies of *BTLA* rs1982809 SNP in stratification analysis. When we conducted an adjustment for gender, age and alcohol consumption, we identified that the *BTLA* rs1982809 G\>A was associated with an increased susceptibility of EGJA for ever smokers (AA versus GG: adjusted OR = 2.09, 95% CI 1.08--4.07, *P* = 0.030; and AA versus GA/GG: adjusted OR = 1.99, 95% CI 1.04--3.82, *P* = 0.039). We found that there was no significant association between *BTLA* rs1982809 G\>A SNP and the risk of EGJA in other subgroups.

###### Stratified analyses between *BTLA* rs1982809 G\>A polymorphism and EGJA risk by sex, age, smoking status and alcohol consumption

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *BTLA* rs1982809 (Case/Control)[^1^](#T4TFN1){ref-type="table-fn"}   Adjusted OR[^2^](#T4TFN2){ref-type="table-fn"} (95% CI); *P*                                                                                      
  --------------------- -------------------------------------------------------------------- -------------------------------------------------------------- ------- ------ -------------------- ------------------------ --------------------- ------------------------
  Sex                                                                                                                                                                                                                                          

    Male                488/605                                                              328/412                                                        49/61   1.00   0.99(0.82--1.20);\   1.01(0.68--1.49);\       0.99(0.83--1.19);\    1.01(0.68--1.49);\
                                                                                                                                                                           *P*: 0.925           *P*: 0.981               *P*: 0.937            *P*: 0.966

    Female              180/241                                                              133/174                                                        27/37   1.00   1.02(0.75--1.37);\   0.99(0.58--1.69);\       1.01(0.76--1.34);\    0.99(0.59--1.66);\
                                                                                                                                                                           *P*: 0.916           *P*: 0.983               *P*: 0.932            *P*: 0.962

  Age                                                                                                                                                                                                                                          

    \<64                304/391                                                              205/287                                                        40/51   1.00   0.92(0.73--1.17);\   1.00(0.64--1.56);\       0.93(0.75--1.17);\    1.04(0.67--1.60);\
                                                                                                                                                                           *P*: 0.502           *P*: 0.996               *P*: 0.553            *P*: 0.876

    ≥64                 364/455                                                              256/299                                                        36/47   1.00   1.07(0.86--1.33);\   0.97(0.61--1.53);\       1.06 (0.86--1.30);\   0.94(0.60--1.48);\
                                                                                                                                                                           *P*: 0.545           *P*: 0.896               *P*: 0.609            *P*: 0.801

  Smoking status                                                                                                                                                                                                                               

    Never               487/606                                                              325/424                                                        50/81   1.00   0.95(0.79--1.15);\   0.78(0.54--1.14);\       0.93(0.77--1.11);\    0.80(0.56--1.15);\
                                                                                                                                                                           *P*: 0.600           *P*: 0.199               *P*: 0.392            *P*: 0.229

    Ever                181/240                                                              136/162                                                        26/17   1.00   1.13(0.83--1.54);\   **2.09(1.08--4.07);**\   1.22(0.91--1.64);\    **1.99(1.04--3.82);**\
                                                                                                                                                                           *P*: 0.449           ***P*: 0.030**           *P*: 0.193            ***P*: 0.039**

  Alcohol consumption                                                                                                                                                                                                                          

    Never               563/737                                                              378/524                                                        63/90   1.00   0.95(0.80--1.13);\   0.92(0.66--1.30);\       0.94(0.80--1.11);\    0.94(0.68--1.32);\
                                                                                                                                                                           *P*: 0.543           *P*: 0.639               *P*: 0.493            *P*: 0.725

    Ever                105/109                                                              83/62                                                          13/8    1.00   1.40(0.91--2.17);\   1.56(0.61--3.99);\       1.42(0.94--2.16);\    1.37(0.54-3.44);\
                                                                                                                                                                           *P*: 0.126           *P*: 0.350               *P*: 0.098            *P*: 0.504
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The genotyping was successful in 1205 (97.49%) EGJA cases, and 1530 (99.35%) controls for *BTLA* rs1982809.

Adjusted for age, sex, smoking status and alcohol consumption (besides stratified factors accordingly) in a logistic regression model.

No association was found between the *BTLA* rs2171513 G\>A, rs3112270 A\>G and rs16859629 T\>C SNPs and the susceptibility of EGJA in subgroup analyses (data was not shown).

SNP haplotypes {#sec3-4}
--------------

Using haplotype constructing software mentioned above \[[@B26]\], we observed 12 *BTLA* gene haplotypes. We identified that TAAG haplotype with the order of *BTLA* rs16859629, rs1982809, rs2171513 and rs3112270 SNPs might increase the susceptibility of EGJA (OR = 3.07, 95% CI = 1.41--6.71; *P* = 0.003). However, other observed *BTLA* gene haplotypes did not alter the susceptibility of EGJA ([Table 5](#T5){ref-type="table"}).

###### BTLA haplotypes frequency (%) and the association between BTLA haplotypes and risk of EGJA

  Haplotypes   Case   Control   Crude OR (95%CI)   *P*                            
  ------------ ------ --------- ------------------ ------- ---------------------- -----------
  TGGA         1159   48.64     1459               48.41   Reference              
  TAGG         407    17.08     518                17.19   0.99(0.85--1.15)       0.887
  TGAA         283    11.88     350                11.61   1.02(0.85--1.21)       0.843
  CGGA         136    5.71      175                5.81    0.98(0.77--1.24)       0.856
  TGAG         120    5.04      154                5.11    0.98(0.76--1.26)       0.88
  TGGG         71     2.98      105                3.48    0.85(0.62--1.15)       0.309
  TAGA         70     2.94      87                 2.89    1.01(0.73--1.40)       0.938
  TAAA         69     2.9       79                 2.62    1.10(0.79--1.53)       0.575
  CAGG         34     1.43      57                 1.89    0.75(0.49--1.16)       0.192
  TAAG         22     0.92      9                  0.3     **3.07(1.41--6.71)**   **0.003**
  CAGA         7      0.29      19                 0.63    0.46(0.19--1.11)       0.076
  Others       5      0.21      2                  0.07    3.15(0.61--16.26)      0.149

With the order of *BTLA* rs16859629 T\>C, rs1982809 G\>A rs2171513 G\>A and rs3112270 A\>G in gene position.

Power calculation and FPRP determining {#sec3-5}
--------------------------------------

Using PS software (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>), the power value (α = 0.05) was calculated \[[@B27],[@B28]\]. For *BTLA* rs1982809 G\>A SNP, the power value was 0.631 in AA versus GG genetic model and 0.589 in AA versus GG/GA genetic model among ever smokers. In haplotype comparison, T~rs16859629~A~rs1982809~A~rs2171513~G~rs3112270~ haplotype could increase the susceptibility of EGJA (power value, 0.830).

Discussion {#sec4}
==========

The incidence of EGJA is increasing in both the East and Western countries. It is reported that altered lifestyle and lower chronic Helicobacter pylori infection may result in an increasing incidence of EGJA \[[@B30],[@B31]\]. The etiology of EGJA may be attribute to gene and environment factors. Recent evidence suggested that the variants of immune and inflammatory response related genes could alter the risk of cancer \[[@B21],[@B32]\]. Considering an important role of *BTLA* gene in immune, we chose *BTLA* tagging SNPs (rs16859629, rs1982809, rs2171513 and rs3112270) and explored their effects on the development of EGJA. Here, we identified that *BTLA* TAAG haplotype with the order of rs16859629, rs1982809, rs2171513 and rs3112270 SNPs might be associated with the development of EGJA.

*BTLA* rs1982809 G\>A SNP locates in 3′-UTR, which could participate in post-transcriptional control. Recently, studies have been conducted to identify a potential effect of *BTLA* rs1982809 locus on the development of malignancy. *BTLA* rs1982809 polymorphism, a 3′-UTR SNP, was found to be associated with the development of renal cell carcinoma in Polish populations \[[@B18]\]. Another case--control study also found that *BTLA* rs1982809 polymorphism were associated with chronic lymphocytic leukemia \[[@B16]\]. Subsequently, in the same study, the funcional investigation demonstrated that the presence of *BTLA* rs1982809 G allele was correlated with lower expression *of BTLA* mRNA in lymphocyte as compared with rs1982809 A allele \[[@B16]\]. In the present study, we first studied the relationship between *BTLA* rs1982809 locus and cancer risk in Asians. We found this SNP might not alter the overall EGJA risk. However, *BTLA* rs1982809 locus was identified as a risk factor to EGJA in smoking subgroup, which was similar to the previous reports \[[@B16],[@B18]\]. The results suggested that the role of *BTLA* rs1982809 G\>A polymorphism may be influenced by environmental factors. However, the subjects included in smoking subgroup were related small, these findings may be underpowered. In the future, more case--control studies should be conducted to evaluate whether *BTLA* rs1982809 G\>A polymorphism might inhibit the function of B and T cells and influence the susceptibility of cancer.

In the present case--control study, the *BTLA* haplotypes were also constructed. We found *BTLA* T~rs16859629~A~rs1982809~A~rs2171513~G~rs3112270~ haplotype might influence the risk of EGJA. However, this rare *BTLA* haplotypes only altered the susceptibility of a minor fraction of the EGJA patients. We first expolre the association of *BTLA* haplotypes with cancer risk in Asians. Our findings should be verified in the future studies.

It is necessary to acknowledge the limitations in the present case--control study. First, the present study was designed as hospital-based. Although the frequencies of genotype distribution in *BTLA* rs16859629, rs1982809, rs2171513 and rs3112270 SNPs met HWE and the MAFs of these selected SNPs in control group were close to the database for Chinese, the bias might have happened. Second, we only included four risk factors (gender, age, smoking and alcohol consumption). And other potential environment factors (e.g. body mass index, intake of vegetable and fruit, education level and economic income) were not considered. Thus, the potential interactions between gene and these environment factors could not addressed. Third, the participants included were related small in some subgroups, the observations may be insufficient evidence to identify a relationship with a definitive power. Fourth, in the present study, the biological functions of *BTLA* SNPs were not studied. Finally, only four *BTLA* tagging SNPs (rs16859629, rs1982809, rs2171513 and rs3112270) were selected, which could not fully assess the total hereditary susceptibility in *BTLA* gene.

To conclude, this investigation suggests that *BTLA* T~rs16859629~A~rs1982809~A~rs2171513~G~rs3112270~ haplotype may increase the susceptibility of EGJA. More studies with multiple environment factors should be carried out to evaluate whether *BTLA* variants may influence the susceptibility of cancer in the future.
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